Medication info

Esapagduo Sustained-Release Tablet 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Pink, bilaterally convex, oval-shaped sustained-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP) * 5], 30 tablets/bottle
Approval status
Active

MFDS item code 202301903 · Approved 2023.06.21

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching to this medication from combination therapy with dapagliflozin and metformin, this medication may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because any change may cause a change in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medication whole; it must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • irregular blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to help control blood sugar levels in adults with type 2 diabetes by combining the effects of dapagliflozin and metformin. It is particularly effective for individuals who are also implementing dietary control and exercise. Additionally, caution is required when using dapagliflozin in patients with cardiovascular diseases or risk factors where blood sugar is not well-controlled. It is important to refer to expert opinions on the safe use of this medication, which ultimately aids in improving blood sugar control.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching to this medication from combination therapy with dapagliflozin and metformin, this medication may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because any change may cause a change in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medication whole; it must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Precautions

This medication is used for diabetes treatment and should not be administered to patients with poor kidney function or acute illnesses. It can rarely cause a serious side effect known as lactic acidosis, so if symptoms such as difficulty breathing, muscle pain, or weakness appear, you should immediately consult a doctor. When used together with insulin or sulfonylurea medications, there is a risk of hypoglycemia, so blood sugar levels should be monitored carefully. Patients with decreased kidney function or dehydration should check their fluid status and kidney function before taking this medication and require regular monitoring during treatment. This medication may increase the risk of genital and urinary tract infections, so prompt treatment should be sought if infection symptoms occur. Women who are pregnant or may become pregnant, as well as those who are breastfeeding, should not use this medication and should discontinue it immediately if pregnancy is confirmed. Elderly patients or those with impaired liver function are at higher risk for side effects when taking this medication, so dose adjustment and careful monitoring are necessary. This medication may interact with some drugs, so if you are taking other medications, you must inform your doctor or pharmacist. In case of overdose, seek medical attention immediately for appropriate treatment, and rapid dialysis may be required. During the use of this medication, be cautious of symptoms like dizziness when driving or operating machinery and keep it out of reach of children.

Side effects

  • Severe metabolic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polydipsia
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendonitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignant neoplasm
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urogenital syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent air and moisture from entering. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, bilaterally convex, oval-shaped sustained-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP) * 5], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.